NASDAQ:NGNE Neurogene Q2 2025 Earnings Report $36.73 +0.59 (+1.63%) As of 01:16 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Neurogene EPS ResultsActual EPS-$1.05Consensus EPS -$1.15Beat/MissBeat by +$0.10One Year Ago EPSN/ANeurogene Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANeurogene Announcement DetailsQuarterQ2 2025Date8/11/2025TimeBefore Market OpensConference Call DateMonday, August 11, 2025Conference Call Time9:30AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Neurogene Earnings HeadlinesWhat is HC Wainwright's Forecast for Neurogene Q3 Earnings?August 16 at 1:15 AM | americanbankingnews.comCanaccord Genuity Group Lowers Neurogene (NASDAQ:NGNE) Price Target to $166.00August 14 at 2:06 AM | americanbankingnews.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.August 17 at 1:00 AM | Chaikin Analytics (Ad)Neurogene Inc. (NASDAQ:NGNE) Given Average Rating of "Buy" by AnalystsAugust 12, 2026 | americanbankingnews.comNeurogene Reports Second Quarter 2026 Financial Results and Highlights Recent UpdatesAugust 11, 2026 | businesswire.comNeurogene (NGNE) Expected to Release Quarterly Earnings on MondayAugust 9, 2026 | americanbankingnews.comSee More Neurogene Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Neurogene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neurogene and other key companies, straight to your email. Email Address About NeurogeneNeurogene (NASDAQ:NGNE), Inc. is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions. Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues. Preclinical studies have demonstrated the potential for sustained biochemical correction and functional improvement, supporting the company’s progression into human clinical trials. Initial studies are under way in North America, and Neurogene plans to expand its clinical footprint into Europe pending regulatory clearances. Headquartered in South San Francisco, California, Neurogene was founded to address the unmet needs of patients and families living with life-threatening genetic disorders of the nervous system. The company’s executive leadership team brings together expertise in gene therapy development, neurology, and biopharmaceutical manufacturing. By targeting diseases with well-defined genetic causes and no approved treatments, Neurogene aims to deliver transformative therapies to patients worldwide.View Neurogene ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Birkenstock Beats the Skeptics—But Not on EPSThese 5 Dividend Stocks Show Why Income Investing Still MattersThe Quantum Race Is Heating Up—And 2 Small Players Stand OutMarketBeat Week in Review – 08/10 - 08/14Applied Materials Beat Everything but Wall Street’s Expectations for MarginsLooking Beyond CrowdStrike? 3 AI Security Stocks Stand Out5 Recession-Proof Stocks Hiding in Cardboard Boxes Upcoming Earnings Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026)Alibaba Group (8/20/2026)Ross Stores (8/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
